Single-Tablet Bictegravir-Lenacapavir Noninferior to Complex Regimens for HIV-1

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 9, 2026.

via HealthDay

MONDAY, March 9, 2026 -- For patients with HIV-1 with virologic suppression on complex multipill regimens, the bictegravir-lenacapavir single-tablet regimen (STR) is noninferior to complex regimens, according to a study published online Feb. 25 in The Lancet.

Chloe Orkin, M.D., from Queen Mary University of London, and colleagues conducted a randomized, noninferiority phase 3 trial involving people with HIV-1 with virologic suppression on complex regimens. Participants were randomly assigned to switch to once-daily oral bictegravir-lenacapavir 75-mg/50-mg STRs or a continued complex regimen (371 and 186, respectively).

The researchers found an HIV-1 RNA viral load of 50 copies/mL or higher in three and two participants receiving bictegravir-lenacapavir and a complex regimen, respectively, at week 48 (both 1 percent; difference −0.3 percent [95.002 percent confidence interval, −2.3 to 1.8], meeting the noninferiority margin). There was no resistance. The groups had similar adverse event rates. Due to adverse events, six and one (2 and 1 percent) participants discontinued bictegravir-lenacapavir and their complex regimen, respectively. Five deaths occurred in the bictegravir–lenacapavir group, none of which were related to the study drug. After switching to bictegravir-lenacapavir, participants reported increased treatment satisfaction.

"This STR could present the first opportunity to optimize treatment while maintaining virological suppression in people taking complex regimens who have not benefited from available STRs due to antiretroviral resistance or other reasons," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including Gilead Sciences, which manufactures bictegravir-lenacapavir and funded the study.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-10 01:46

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords